Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
Holding SLNO?
Track your performance easily
SLNO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$21.39 - $59.75
Previous Close$59.18
Volume430.96K
Average Volume (3M)631.13K
Market Cap
$2.55B
Enterprise Value$2.30B
Total Cash (Recent Filing)$256.78M
Total Debt (Recent Filing)$3.03M
Price to Earnings (P/E)―
Beta-0.65
Next Earnings
Mar 25, 2025EPS Estimate
-$1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding43,117,432
10 Day Avg. Volume500,264
30 Day Avg. Volume631,132
Standard Deviation0.70
R-Squared0.01
Alpha0.12
Financial Highlights & Ratios
Price to Book (P/B)9.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-41.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-18.11
Forecast
1Y Price Target
$74.86Price Target Upside30.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Soleno Therapeutics News
PremiumCompany Announcements
Soleno Therapeutics Reports Q3 Progress and Financials
PremiumPre-Earnings
Is SLNO a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessDCCR achieved placebo-controlled statistical significance on the primary endpoint, which strengthens its case for approval.
Financial PositionAs of September 30, Soleno had cash, equivalents, and marketable securities of $284.7M, indicating a strong financial position.
Regulatory ProgressThe FDA accepted the NDA for DCCR with priority review, indicating a fast-tracked process due to its potential impact on a high unmet need patient population.
Bears Say
Financial PerformanceSoleno reported a net loss of $1.83 per share, driven by substantially higher-than-expected operating expenses.
Obligations And LiabilitiesThe company is obligated to make cash payments up to $21.2M to former Essentialis stockholders upon achieving certain commercial milestones.
Revenue And LossSoleno reported no revenue and a significantly higher loss than consensus estimates due to the granting of restricted stock units.
---
Ownership Overview
17.78% Insiders
10.06% Mutual Funds
12.19% Other Institutional Investors
51.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLNO FAQ
What was Soleno Therapeutics Inc’s price range in the past 12 months?
Soleno Therapeutics Inc lowest stock price was $21.39 and its highest was $59.75 in the past 12 months.
What is Soleno Therapeutics Inc’s market cap?
Currently, no data Available
When is Soleno Therapeutics Inc’s upcoming earnings report date?
Soleno Therapeutics Inc’s upcoming earnings report date is Mar 25, 2025 which is in 121 days.
How were Soleno Therapeutics Inc’s earnings last quarter?
Soleno Therapeutics Inc released its earnings results on Nov 06, 2024. The company reported -$1.83 earnings per share for the quarter, missing the consensus estimate of -$0.605 by -$1.225.
Is Soleno Therapeutics Inc overvalued?
According to Wall Street analysts Soleno Therapeutics Inc’s price is currently Undervalued.
Does Soleno Therapeutics Inc pay dividends?
Soleno Therapeutics Inc does not currently pay dividends.
What is Soleno Therapeutics Inc’s EPS estimate?
Soleno Therapeutics Inc’s EPS estimate is -$1.04.
How many shares outstanding does Soleno Therapeutics Inc have?
Soleno Therapeutics Inc has 43,117,430 shares outstanding.
What happened to Soleno Therapeutics Inc’s price movement after its last earnings report?
Soleno Therapeutics Inc reported an EPS of -$1.83 in its last earnings report, missing expectations of -$0.605. Following the earnings report the stock price went up 0.44%.
Which hedge fund is a major shareholder of Soleno Therapeutics Inc?
Among the largest hedge funds holding Soleno Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Soleno Therapeutics Inc’s shares valued at 131M.
---
Soleno Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.86 (30.62% Upside)
$74.86 (30.62% Upside)
Blogger Sentiment
Bullish
SLNO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 470.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $58.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 28.2%
Last 30 Days ▲ 28.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.00%
12-Months-Change
Fundamentals
Return on Equity
-91.11%
Trailing 12-Months
Asset Growth
366.90%
Trailing 12-Months
Company Description
Soleno Therapeutics Inc
Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It markets CoSense End-Tidal Carbon Monoxide monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
---
SLNO Stock 12 Month Forecast
Average Price Target
$74.86
▲(30.62% Upside)
Technical Analysis
Best Analysts Covering SLNO
1 Year
1 Year Success Rate
8/8 ratings generated profit
1 Year Average Return
+21.40%
assigned a buy rating 18 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +21.40% per trade.
---